The Zhitong Finance App learned that BridgeBio Pharma (BBIO.US) announced on Wednesday that its heart disease treatment acoramidis (US brand name: Attruby) performed better than Pfe.US (PFE.US) competitor drug tafamidis (US brand name Vyndamax) in a real-world study.

Zhitongcaijing · 3d ago
The Zhitong Finance App learned that BridgeBio Pharma (BBIO.US) announced on Wednesday that its heart disease treatment acoramidis (US brand name: Attruby) performed better than Pfe.US (PFE.US) competitor drug tafamidis (US brand name Vyndamax) in a real-world study.